Эстония - эстонский - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsioonipulber - 4,5mcg+160mcg 1annus 120annus 10tk; 4,5mcg+160mcg 1annus 60annus 1tk; 4,5mcg+160mcg 1annus 120annus 18tk; 4,5mcg+160mcg 1annus 60annus 18tk; 4,5mcg+160mcg 1annus 60annus 2tk; 4,5mcg+160mcg 1annus 120annus 3tk; 4,5mcg+160mcg 1annus 60annus 3tk; 4,5mcg+160mcg 1annus 60annus 10tk; 4,5mcg+160mcg 1annus 120annus 2tk; 4,5mcg+160mcg 1annus 30annus 1tk; 4,5mcg+160mcg 1annus 120annus 1tk

Эстония - эстонский - Ravimiamet

astrazeneca uk limited - meropeneem - süste-/infusioonilahuse pulber - 1g 1tk; 1g 10tk

Эстония - эстонский - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsioonipulber - 9mcg+320mcg 1annus 60annus 10tk; 9mcg+320mcg 1annus 60annus 18tk; 9mcg+320mcg 1annus 60annus 1tk

Эстония - эстонский - Ravimiamet

astrazeneca ab - esomeprasool - süste-/infusioonilahuse pulber - 40mg 1tk; 40mg 10tk

Эстония - эстонский - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsiooniaerosool, suspensioon - 4,5mcg+160mcg 1mõõtannus 120mõõtannus

Эстония - эстонский - Ravimiamet

astrazeneca uk limited - meropeneem - süste-/infusioonilahuse pulber - 500mg 1tk

Эстония - эстонский - Ravimiamet

astrazeneca ab - formoterool+budesoniid - inhalatsiooniaerosool, suspensioon - 2,25mcg+80mcg 1mõõtannus 60mõõtannus 1tk; 2,25mcg+80mcg 1mõõtannus 120mõõtannus 1tk

Европейский союз - эстонский - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Европейский союз - эстонский - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukeemia, lümfotsüütne, krooniline, b-rakk - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Европейский союз - эстонский - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leukeemia, karvane rakk - antineoplastilised ained - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).